

Evidence dossier - Avoro Capital Advisors

GetCoattail manager profile: <https://getcoattail.com/manager/avoro-capital-advisors> | CIK 0001633313 | Rank #39 of 149 tracked managers by reported 13F value.

Background: Founded: 2010 | HQ: New York, New York, United States | Style: Long-term life sciences / biotechnology investing in emerging biotech companies | Key person: Behzad Aghazadeh

Background source: <https://www.owler.com/company/avorocapital>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-14 Reported total value: \$11.1B Positions: 26 Top-10 concentration: 79.5% of reported value.

Ticker	Company	Weight	Reported value
UTHR	United Therapeutics Corp	13.52%	\$1.5B
ASND	Ascendis Pharma	12.24%	\$1.4B
KRYS	Krystal Biotech Inc	9.64%	\$1.1B
MDGL	Madrigal Pharmaceuticals Inc	8.84%	\$984M
ARGX	Argenx Se	8.33%	\$928M
ARWR	Arrowhead Pharmaceuticals Inc	8.31%	\$926M
KYMR	Kymera Therapeutics Inc	7.70%	\$857M
RVMD	Revolution Medicines Inc	3.86%	\$430M
CYTK	Cytokinetics Inc	3.82%	\$426M
CELC	Celcuity Inc	3.19%	\$356M

2. Hypothetical 13F-clone results

WITHHELD for this manager. Price coverage of the disclosed portfolio is too low for a representative clone (latest-filing value coverage and the average unpriced segment weight are stated in section 4): a clone computed from the priced minority would misrepresent the disclosed portfolio. The filing snapshot above and the filing history below are complete as reported.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001144204-16-134109	2016-11-14	43
2016Q4	0001144204-17-008458	2017-02-14	38
2017Q1	0001144204-17-027247	2017-05-15	41
2017Q2	0001144204-17-042909	2017-08-14	41
2017Q3	0001144204-17-058791	2017-11-14	38
2017Q4	0001144204-18-008486	2018-02-14	43

2018Q1	0001144204-18-028636	2018-05-15	49
2018Q2	0001144204-18-044364	2018-08-14	40
2018Q3	0001144204-18-059659	2018-11-14	42
2018Q4	0001144204-19-007742	2019-02-14	32
2019Q1	0001144204-19-026372	2019-05-15	31
2019Q2	0001144204-19-039861	2019-08-14	33
2019Q3	0001104659-19-063991	2019-11-14	33
2019Q4	0001104659-20-020938	2020-02-14	29
2020Q1	0001104659-20-062350	2020-05-15	41
2020Q2	0001104659-20-095150	2020-08-14	44
2020Q3	0001104659-20-125482	2020-11-16	46
2020Q4	0001104659-21-023460	2021-02-16	43
2021Q1	0001104659-21-067522	2021-05-17	46
2021Q2	0001104659-21-105761	2021-08-16	44
2021Q3	0001104659-21-138678	2021-11-15	43
2021Q4	0001104659-22-021801	2022-02-14	40
2022Q1	0001104659-22-060934	2022-05-16	43
2022Q2	0001104659-22-090675	2022-08-15	40
2022Q3	0001104659-22-117974	2022-11-14	39
2022Q4	0001104659-23-020884	2023-02-14	36
2023Q1	0001104659-23-060303	2023-05-15	38
2023Q2	0001104659-23-090901	2023-08-14	43
2023Q3	0001104659-23-117606	2023-11-14	45
2023Q4	0001104659-24-023272	2024-02-14	42
2024Q1	0001104659-24-061613	2024-05-15	46
2024Q2	0001104659-24-089335	2024-08-14	41
2024Q3	0001104659-24-118335	2024-11-14	35
2024Q4	0001104659-25-013529	2025-02-14	39
2025Q1	0001104659-25-048904	2025-05-15	33
2025Q2	0001104659-25-078127	2025-08-14	30
2025Q3	0001104659-25-111932	2025-11-14	30
2025Q4	0001104659-26-015748	2026-02-17	33
2026Q1	0001104659-26-061754	2026-05-15	30
2026Q2	0001104659-26-096427	2026-08-14	26

4. Coverage and adjustments

Price coverage at the latest filing: 63.1% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.